HealthSouth Corp stock hits 52-week high at $121.96

HealthSouth Corp (NYSE:EHC) stock soared to a 52-week high, reaching a price level of $121.96, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" overall financial health score, with particularly strong profitability metrics. This peak reflects a robust year-over-year performance, with the stock witnessing an impressive 41% increase in value over the past year. Investors have shown growing confidence in HealthSouth’s market position and future prospects, supported by eight analysts revising their earnings upward for the upcoming period. The company’s strong fundamentals are further evidenced by its 42% gross profit margin and consistent dividend payments for 13 consecutive years. For deeper insights into EHC’s valuation and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers this and 1,400+ other top US stocks.

In other recent news, Encompass Health has reported several noteworthy developments. The company announced a quarterly cash dividend of $0.17 per share, payable on July 15, 2025, to shareholders of record as of July 1, 2025. This follows a strong first-quarter performance in 2025, with earnings surpassing expectations and prompting Mizuho (NYSE:MFG) Securities to raise its price target for Encompass Health to $130, maintaining an Outperform rating. Similarly, RBC Capital Markets increased its price target to $125, citing the company’s robust first-quarter results and a favorable shift in its payer mix. KeyBanc Capital Markets also adjusted its outlook, lifting the price target to $135 due to a supply-demand imbalance in the inpatient rehabilitation facility sector.

Encompass Health’s shareholders approved the 2025 Omnibus Performance Incentive Plan, aligning executive and director interests with those of shareholders. The plan aims to provide performance-based compensation to key company officers. Additionally, the election of 10 board members and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were approved. The company’s first-quarter results and subsequent analyst revisions reflect strong patient volumes and effective expense management, contributing to positive financial projections. These developments highlight Encompass Health’s ongoing strategic initiatives and the confidence analysts have in its future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.